Global Flow Cytometry in Oncology Market to Reach $5.25 Bn by 2031

Wednesday 9 June 2021, Amsterdam

The global flow cytometry in oncology market is projected to reach $5.25 billion by 2031, reveals the premium market intelligence study. The study also highlights that the market is set to witness a CAGR of 12.02% during the forecast period 2021-2031.

The comprehensive study of the global flow cytometry in oncology market extensively covers the following:

• Market numbers on micro-segments that are influencing the market
• More than 200 products present in the market
• Evaluation of over 25 brands
• Market share analysis for more than 20 product categories
• End-user preference data for over 50 end users
• Detailed global and regional market share analysis including the scrutiny of more than 16 countries
• Study of more than 25 companies’ data

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 200+ products.

This study indicates that the rising incidence of hematological malignancies, increasing fund infusions for hematological malignancies, and growing consumer awareness for tailored therapy and precision medicine in the market are fueling the growth of the global flow cytometry in oncology market.

The market intelligence is additionally throws a spotlight on the opportunities existing in the market, such as technological evolution in the field of flow cytometry and growth in solid tumor applications of flow cytometry.

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include product type, technology, type of cancer, applications, end users, and regions. The type of cancer, application, and the region segments have been further sub-segmented to offer an in-depth analysis of the global flow cytometry in oncology market.

The product and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analyses of preferred flow cytometry in oncology products. Pertaining to the market segmentation, the product segment is segmented into assays and kits, instruments, reagents and consumables, and software. The technology segment has been segregated into cell-based and bead-based. The type of cancer segment has been broadly segmented into hematological malignancies and solid tumor. In addition, the hematological malignancies have been further segmented into lymphoma, leukemia, myeloma, and other hematological malignancies. Similarly, the solid tumors segment has been further segmented into breast cancer, prostate cancer, colorectal cancer (CRC), lung cancer, and other solid tumors. Further, the application segment of the market has been broadly segmented into translational research and clinical applications. The clinical applications segment has been further segmented to screening and diagnostics and treatment monitory. Moreover, the end user segment in the market has been classified into diagnostic laboratories, hospitals and healthcare clinics, academic and research institutions, and other end users.

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, bioAffinity Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytek Biosciences, Cytognos, S.L., Danaher Corporation, Miltenyi Biotec B.V. & Co. KG, Laboratory Corporation of America Holdings, Luminex Corporation, NeoGenomics Laboratories, Inc., Sony Corporation, and Thermo Fisher Scientific Inc.

The study also offers strategic recommendations that can help organizations in tracking various products and trends that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.